PTK2 and neoplasm: This co-delivery nanosystem of Cet and siFAK demonstrated enhanced Cet loading and prevented the degradation of siFAK, thereby enabling the targeted release of these agents in tumor tissues and targeted knockdown of the pro-carcinogenic gene FAK. In vivo and in vitro experiments confirmed the pH-responsiveness and biosafety of Cet/siFAK@ZIF-8@TCM and its anti-LSCC progression advantages, thereby providing a new, feasible, and clinically promising drug delivery strategy for the treatment of LSCC.